Windtree Therapeutics, Inc. P/B ratio

P/B ratio of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/B ratio growth rates and interactive chart. Measures the relationship between price and book value per share. Book value is the equity or owner's capital that is invested in a business. If a stock has a price of $10 and a book value per share of $10, the ratio is 1. Stock selling below a P/B of 1 can be a bargain, as the market price has declined below the net asset value of the business. It is more applicable to financial companies like banks and insurers, as their assets and liabilities are valued at market and the book value thus more accuraterly represents reality.


Highlights and Quick Summary

Current P/B ratio of Windtree Therapeutics, Inc. is 1.86 (as of December 30, 2019)
  • P/B ratio for the quarter ending December 30, 2019 was 1.86 (a -26.84% decrease compared to previous quarter)
  • Year-over-year quarterly P/B ratio increased by 463.74%
  • Annual P/B ratio for 2019 was 1.86 (a 463.74% increase from previous year)
  • Annual P/B ratio for 2018 was 0.33 (a Infinity% increase from previous year)
  • Annual P/B ratio for 2017 was 0.0 (a NaN% decrease from previous year)
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/B ratio of Windtree Therapeutics, Inc.

Most recent P/B ratioof WINT including historical data for past 10 years.

Interactive Chart of P/B ratio of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. P/B ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 1.86 2.54 2.2 1.86
2018 0.33 0.0 0.0 0.0 0.33
2017 0.0 0.0 0.0 0.0 0.0
2016 0.0 0.0 0.0 0.0 0.0
2015 2.48 1.77 0.0 13.04 2.48
2014 5.14 5.41 3.86 3.73 5.14
2013 2.13 19.61 4.76 10.65 2.13
2012 4.71
2011 5.87 1.99 30.68

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.